The effects of propranolol on heart rate variability and quantitative, mechanistic, pain profiling

*a randomized placebo-controlled crossover study*

Petersen, Kristian Kjær; Andersen, Hjalte Holm; Tsukamoto, Masato; Tracy, Lincoln; Koenig, Julian; Arendt-Nielsen, Lars

*Published in:*
Scandinavian Journal of Pain

*DOI (link to publication from Publisher):*
10.1515/sjpain-2018-0054

*Publication date:*
2018

*Document Version*
Publisher's PDF, also known as Version of record

*Link to publication from Aalborg University*

*Citation for published version (APA):*

*General rights*
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

*Take down policy*
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.
The effects of propranolol on heart rate variability and quantitative, mechanistic, pain profiling: a randomized placebo-controlled crossover study

Kristian Kjær Petersen*, Hjalte Holm Andersen, Masato Tsukamoto, Lincoln Tracy, Julian Koenig and Lars Arendt-Nielsen

Original experimental

Abstract

Background and aims: The autonomic nervous system (ANS) is capable of modulating pain. Aberrations in heart rate variability (HRV), reflective of ANS activity, are associated with experimental pain sensitivity, chronic pain, and more recently, pain modulatory mechanisms but the underlying mechanisms are still unclear. HRV is lowered during experimental pain as well as in chronic pain conditions and HRV can be increased by propranolol, which is a non-selective β-blocker. Sensitization of central pain pathways have been observed in several chronic pain conditions and human mechanistic pain biomarkers for these central pain pathways include temporal summation of pain (TSP) and conditioned pain modulation (CPM). The current study aimed to investigate the effect of the β-blocker propranolol, and subsequently assessing the response to standardized, quantitative, mechanistic pain biomarkers.

Methods: In this placebo-controlled, double-blinded, randomized crossover study, 25 healthy male volunteers (mean age 25.6 years) were randomized to receive 40 mg propranolol and 40 mg placebo. Heart rate, blood pressure, and HRV were assessed before and during experimental pain tests. Cuff pressure pain stimulation was used for assessment of pain detection (cPDTs) and pain tolerance (cPTTs) thresholds, TSP, and CPM. Offset analgesia (OA) was assessed using heat stimulation.

Results: Propranolol significantly reduced heart rate ($p<0.001$), blood pressure ($p<0.02$) and increased HRV ($p<0.01$) compared with placebo. No significant differences were found comparing cPDT ($p>0.70$), cPTT ($p>0.93$), TSP ($p>0.70$), OA-effect ($p>0.87$) or CPM ($p>0.65$) between propranolol and placebo.

Conclusions: The current study demonstrated that propranolol increased HRV, but did not affect pressure pain sensitivity or any pain facilitatory or modulatory outcomes.

Implications: Analgesic effects of propranolol have been reported in clinical pain populations and the results from the current study could indicate that increased HRV from propranolol is not associated with peripheral and central pain pathways in healthy male subjects.

Keywords: β-blockers; heart rate variability; conditioned pain modulation; offset analgesia; temporal summation of pain; pressure pain threshold.

1 Introduction

Propranolol is a non-selective β-blocker originally used to treat portal hypertension [1], but has also been applied as
an anxiolytic [2] and migraine prophylactic [3]. Propranolol exerts its antihypertensive effects by blocking both the β-1 (resulting in a reduction of cardiac output and splanchnic blood flow) and β-2 (resulting in splanchnic vasoconstriction due to unopposed activation of adrenergic α1 receptors) receptors [4]. In addition, propranolol has indirect-acting parasympathomimetic effects, whereby it increases heart rate variability (HRV) [5] – a common measure of the relative contributions of parasympathetic activity in the autonomic control of the heart.

Low HRV has been proposed as a marker for cardiovascular diseases [6–8] and accumulating evidence suggests a close relationship between the autonomic nervous system (ANS) and pain processing [9–11], where HRV is found lowered during experimental pain as well as in chronic pain conditions [9, 12]. Furthermore, reduced HRV has also been associated with increased pain in fibromyalgia [13], and increased post-surgical pain [14]. Administration of propranolol has been shown to alleviate pain in fibromyalgia [15], and temporomandibular joint disorder (TMD) [16]. In addition, propranolol can minimize opioid-induced mechanical and thermal hyperalgesia [17], indicating that propranolol can modulate peripheral and central pain pathways. Administration of Catechol-O-methyltransferase inhibitors in rodents produces increased pain sensitivity at multiple body sites [18, 19], but this pain sensitivity can be blocked by administration of the nonselective β-adrenergic receptor antagonists such as propranolol [19, 20]. Likewise, intramuscular injection of serotonin in humans generates pain [21], which again can be reduced by co-administration of propranolol [22]. There are several mechanisms of which propranolol could mediate the analgesic effects such as peripheral blocking of the β-2-receptors [20, 23], or by blocking of the serotonin receptors in the central nervous system [24]. In spite of the evidence implicating ANS activity and pain processing is unclear, and studies have yet to investigate the potential role of the ANS in the modulation of central pain processing. The aim of this study was to investigate the effect of propranolol on CPM, with secondary outcome measures being experimental pain assessments such as pressure pain thresholds, TSP, and OA. We hypothesized that propranolol would increase HRV and in turn decrease pain sensitivity.

2 Methods

2.1 Study design

The study used a randomized, placebo-controlled, double-blinded, crossover design, with the two experimental sessions being separated by at least 1 week. A single 40 mg dose of propranolol was used as a drug model of parasympathomimetic activation. An identical looking capsule (containing 40 mg calcium) was administrated as placebo. On each study day, the subjects were administered either propranolol or placebo in a randomized order. The experimental assessments were conducted 2 h after administration, corresponding to the expected peak plasma concentration of propranolol [38]. The experimental sequence for pain assessments was: pressure pain thresholds, TSP, OA, and CPM. HRV was recorded prior to and during the CPM testing in each session.

2.2 Participants

Izumi et al. [39] found a CPM effect of 12 kPa (SD: 10 kPa) and this study was designed to find a change in CPM of at least 75%, with a power of 80% with a significant level of 0.05, why 25 healthy men, mean age 25.6 (range: 20–37) years, were recruited from July 2016 to January 2017. Participants were excluded if they suffered from any concomitant pain conditions, used any analogics, lacked understanding of the procedures, had any history of alcohol or drug misuse, were diagnosed with cardiovascular diseases, asthma, diabetes, or had known decreased function of the liver or kidneys. All participants were given
oral and written information and signed written informed consent prior to the initiation of the study. The study complied with the Helsinki Declaration, was approved by the local Ethical Committee (reference number: N-20120043), and registered at ClinicalTrials.gov (registration number: NCT02808611).

2.3 Cardiovascular and heart rate variability measures

Blood pressure was recorded with subjects relaxing in a supine position for 5 min before the commencement of the experimental tests using the Omron Automatic Blood Pressure Monitor, Model: M3 (Imron Healthcare, Kyoto, Japan). Heart rate and HRV were assessed using a Polar RS800CX heart rate monitor (Polar Electro, Kempele, Finland) and all measurements were recorded for 5 min. An elastic chest band with built-in recording electrodes (wetted before use) was placed horizontally immediately below the papilla mammaria. The Polar RS800CX has been used in a number of empirical investigations, and is reliable for assessments in a supine position at rest [40]. The device records interbeat intervals (IBI) at a sampling frequency of 1,000 Hz, providing a temporal resolution of 1 ms for each R–R interval. Timestamps were inserted for the baseline recordings (prior to experimental tests) and during CPM paradigms. The following time-domain measures were derived from analysis in Kubios HRV: mean IBI (ms), the square root of the mean squared difference of successive R–R intervals (rMSSD, ms), and the percentage of adjacent cycles that are greater than 50 ms apart (pNN50, %), which is in line with previous studies in this field [41–43]. Measures from the frequency-domain were not analyzed, since they have recently been heavily criticized. Both rMSSD and pNN50 reflect vagal-parasympathetic activity [9].

2.4 Sudomotor activity

Skin conductance measurements were performed by galvanic skin resistance measurements with a DermaLab USB Hydration eight-pin probe (Cortex Technology ApS, Hadsund, Denmark), as a measure of sudomotor activity and a proxy for sympathetic activity in the ANS. The probe was gently wiped off in a cotton cloth before each assessment. Measurements were performed in duplicate on the index and middle fingers and an average was used for statistical analysis. Skin conductance was assessed before the experimental tests and 30 s after cuff or CPT conditioned pain in according with a previous study [41].

2.5 Experimental pain assessments

2.5.1 Pressure pain thresholds

Pressure stimulation was applied by a computer-controlled cuff algometer (Cortex Technology ApS, Hadsund, Denmark and Aalborg University, Aalborg, Denmark). A 13 cm wide air-cuff (VBM, Sulz am Neckar, Germany) was wrapped around the belly of the gastrocnemius muscle, centering approximately at the level of the lower leg with the maximum circumference, and was inflated at a rate of 1 kPa/s. The participants were instructed to rate the pain intensity of the cuff pressure stimulus on a handheld 10 cm computerized VAS where zero denotes “no pain”, and 10 denotes “worst imaginable pain”. The pressure at VAS = 1 was defined as cuff pressure pain detection threshold (cPDT) [44, 45], and the pressure at which participants felt the pain became intolerable was defined as the pressure pain tolerance threshold (cPTT).

2.5.2 Temporal summation of pain

Ten identical pressure stimuli, equivalent to a pressure at individual cPTT-level, with 1 s duration and 1 s inter-stimulus interval, were applied to induce TSP. Subjects were asked to rate their pain intensity continuously during sequential stimulation on the VAS. In addition, subjects were instructed not to return the VAS to zero in-between the 10 stimulations. The VAS score after each stimulus were extracted, as commonly done when assessing TSP using cuff algometry [46–48]. For analysis of TSP, the mean VAS score was calculated in the interval from the first to the end of the fourth stimulus (VAS-I) and in the interval from the eighth to the end of the 10th stimulus (VAS-II). Temporal summation of pain was defined as the difference between VAS-I and VAS-II (i.e. VAS-II minus VAS-I), which is commonly used when assessing TSP using cuff algometry [46, 47].

2.5.3 Offset analgesia

Heat stimulations were applied using the Pathway Neurosensory Analyzer (Medoc ltd., Ramat Yishai, Israel) and the ATS 30 × 30 mm squared probe. First, a constant control stimulus of 48°C was applied to the dorsal forearm for 30 s. After a short break, the offset analgesia paradigm was applied in three intervals T1 (5 s), T2 (5 s), and T3 (20 s) with temperatures during the trials selected as follows: T1 = 48°C, T2 = 49°C, and T3 = 48°C. The subjects were
asked to assess the pain of the thermal stimuli using the electronic VAS (VAS$_{0-10}$ with 0 = “no pain” and 10 = “worst imaginable pain”). The analgesic effects have been documented to take place after the decrease of the temperature from T2 to T3 (49 °C–48 °C) [30, 49]. The average pain ratings following the decrease from T2 to T3, i.e. in the time interval between 16 s and 20 s (due to the delay of the thermodes to reach the target temperature and the responses latency) were calculated. The window-time used for statistical analysis of OA-effect was adapted based on previous studies [30, 49].

2.5.4 Conditioned pain modulation

CPM was measured using two protocols for test stimuli (TS) and two conditioning stimuli (CS). cPDT was applied as the TS on the dominant leg and one protocol applied 70% of cPTT as CS on the non-dominant leg while the other protocol applied the cold pressor test as CS where the subjects were instructed to immerse the non-dominant hand up to the wrist into the stirred ice-cold water (0–4 °C). The subjects were allowed to withdraw their hand from the ice-water if it became too painful, but were instructed re-immersing their hand and aim the pain rating for approximately VAS = 7, which has previously been applied in comparable studies [50, 51]. Both CS were applied for 5 min to allow for the HRV measures to be conducted.

The CPM-effect was calculated as the differences in pressure needed to evoke cPDT while conditioned subtracted from cPDT at baseline (unconditioned). A 15 min break was included between the two CPM tests to avoid carry-over effects [52]. Subjects completed both CPM protocols that were randomized in order. Pain ratings from both cuff and CPT conditioned stimuli were recorded.

2.5.5 Statistical analysis

All values are presented as mean and standard error of mean (±SEM) if not otherwise indicated. Visual inspection confirmed normal distribution of data. Data were tested for normality using QQ-plots and the Kolmogorov-Smirnov normality test. The rMSSD data were log-transforms to achieve normality.

The effects of propranolol compared to placebo on ANS activity and sensory tests were analysis using repeated measures analysis of variance (rm-ANOVA) with drug (propranolol, placebo) as the main factor. For OA, the paradigm (constant, OA-paradigm) factor was added to investigate the difference in pain rating from a constant 48 °C stimulus to a OA-paradigm. For CPM, a paradigm (cPDT baseline, cPDT conditioned) factor was added to investigate the inhibitory response from a baseline cPDT to cPDT during a conditioned stimuli. To investigate changes in HRV measures during the conditioned stimuli, a time (baseline, during conditioned) factor was added for both CPT and tonic cuff conditioning stimuli.

The statistical analyses were performed by SPSS (version 23, IBM Corporation, NY, USA). p-Values <0.05 were considered as significant.

3 Results

3.1 The effect of propranolol on heart rate and blood pressure

Propranolol significantly reduced heart rate ($F_{(1,24)} = 25.89$, $p < 0.001$) as well as diastolic and systolic blood pressure ($F_{(1,24)} = 6.89$, $p = 0.015$) compared with placebo (Table 1). No adverse event were observed.

3.1.1 Pressure pain sensitivity

No statistical drug effect was found for cPDT ($F_{(1,24)} = 0.15$, $p = 0.70$) or cPTT ($F_{(1,24)} = 0.01$, $p = 0.93$) when comparing propranolol to placebo, indicating that propranolol did not influence pressure pain sensitivity (Fig. 1).

<table>
<thead>
<tr>
<th></th>
<th>Propranolol</th>
<th>Placebo</th>
<th>Effect size (Cohen’s d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beats/min)</td>
<td>55.99 (SD: 6.21)$^*$</td>
<td>61.64 (SD: 7.30)</td>
<td>1.96</td>
</tr>
<tr>
<td>Blood pressure (systolic/diastolic, mmHg)</td>
<td>112.04/68.44$^*$ (SD: 13.42/9.42)</td>
<td>116.08/70.28 (SD: 10.81/7.71)</td>
<td>0.53/0.21</td>
</tr>
</tbody>
</table>

The effect size was calculated using Cohen’s d. mmHg = millimeter of mercury. $^*$Indicate $p < 0.05$ comparing propranolol to placebo.
3.1.2 Temporal summation of pain

The rm-ANOVA showed no difference in TSP comparing propranolol and placebo ($F_{(1,24)} = 0.16, p = 0.70$), indicating that propranolol did not influence pain facilitation in the central nervous system (Fig. 2).

3.1.3 Offset analgesia

A significantly decreased pain rating was found for the OA-paradigm compared with the baseline-paradigm ($F_{(1,24)} = 15.70, p = 0.001$), indicative of functional OA in the study sample. No significant drug effect was found ($F_{(1,24)} = 0.03, p = 0.87$), indicating that propranolol did not affect offset pain modulation (Fig. 3).

3.1.4 Conditioned pain modulation

Pain ratings to CPT (mean VAS: 6.65, SEM: 0.29) was significantly increased compared with cuff (mean VAS: 6.06, SEM: 0.27) conditioning stimuli ($p = 0.048$). cPDT significantly increased during conditioning pain stimulation using both the CPT and a tonic cuff stimulus (rm-ANOVA: $F_{(1,24)} > 17.49, p < 0.001$). There was no effect of drug (rm-ANOVA: $F_{(1,24)} = 0.22, p = 0.65$), signifying functional CPM was unaffected by propranolol (Fig. 4).

3.1.5 The effect of propranolol and tonic cuff and cold presessor test stimuli on the autonomic nervous system

A significant drug effect was found at baseline (prior to experimental tests), showing that compared to placebo, administration of propranolol resulted in a significantly increased mean IBI ($F_{(1,24)} = 28.85, p < 0.001$, Fig. 5A), rMSSD ($F_{(1,24)} = 7.44, p = 0.01$, Fig. 5B), and pNN50 ($F_{(1,24)} = 12.28, p = 0.002$, Fig. 5C). There was no effect of propranolol on skin conductance ($F_{(1,24)} = 0.93, p = 0.34$; Fig. 5D) compared with placebo prior to experimental tests.
A significant time effect comparing ANS activity during CPT to baseline (prior to CPT), showed increased heart rate ($F_{(1,24)} = 8.71, p = 0.01$), rMSSD ($F_{(1,24)} = 6.11, p = 0.021$, Fig. 5B), and decreased mean IBI ($F_{(1,24)} = 8.70, p = 0.01$, Fig. 5A). In addition, a significant time effect was seen for both cuff and CPT compared with baseline (prior to cuff and CPT, respectively), which showed increased skin conductance ($F_{(1,24)} > 15.89, p < 0.005$, Fig. 5D).

4 Discussion

The present randomized, placebo-controlled, crossover study showed that propranolol exerts a parasympathomimetic effect, decreasing heart rate and blood pressure, while increasing measures of vagally-mediated HRV, compared to placebo. However, propranolol did not affect the quantitative, mechanistic pain biomarkers (pressure pain thresholds, temporal summation of pain, offset analgesia, or conditioned pain modulation) in healthy male volunteers.

4.1 Pain and the automatous system

The parasympathetic vagus nerve influences pain. For instance, vagotomy increases pain, and stimulation of the vagus nerve reduces thermal pain sensitivity in both animal [53–55] and human [56, 57] studies. Afferent baroreceptor signaling has been suggested to modulate pain perception via medullary and mesencephalic neural circuitry that modulates descending pain inhibition [58, 59]. Lowered parasympathetic activity has been associated with increased ratings of pain in response to thermal stimuli in healthy subjects [60, 61], patients with fibromyalgia [62], and in patients...
with chemotherapy-induced polyneuropathy [63]. A recent study found propranolol to reduce measures of central sensitization in a migraine rat model [64] and two human experimental pain studies suggest that propranolol has potential antihyperalgesic effects although the mechanism(s) involved remain elusive or perhaps related to off-target interactions [17, 22] – a finding not supported by the present study. Transcutaneous-vagus nerve stimulation increases HRV [65] and have been found to increase mechanical and pressure pain thresholds and reduce mechanical pain sensitivity [56] in healthy males and to reduced evoked pain intensity and TSP in patients with chronic pelvic pain [66].

Increase HRV can be achieved by other pharmaceutical approaches, such as Scopolamine [67, 68] or Atropine [69, 70], or non-pharmacological, such as transcutaneous-vagus nerve stimulation [65] or deep breathing [71], and future studies could investigate if these have different effects on the central pain mechanisms investigated in the current study.

### 4.2 Pressure pain thresholds

Pain thresholds are commonly used to assess alterations in pain sensitivity following acute or chronic injury. However, pain thresholds exhibit high inter-individual variability, which is believed to be driven by factors such as genotype [72], sex [73], psychological state [74], and ANS activity [9]. Despite this, the intra-individual reliability of pressure pain thresholds has been documented as good-to-excellent in studies assessing the intra- and inter-session [50, 75] reliability. Clinically, patients with chronic pain conditions such as osteoarthritis [26], migraine [76], or fibromyalgia [27] show lower pressure pain thresholds compared to pain-free individuals. Therefore, understanding the variability related to pressure pain threshold testing is critical for future clinical use. In this context, the ANS has been suggested to be associated with experimental pain outcomes, and some of the variance found in pain threshold testing [9]. The current study administrated a β-blocker, evoking an increased HRV, but found the β-blocker to have no effect on pressure pain detection or tolerance thresholds compared with placebo. These results indicate that a small but significant increase in HRV does not alter pain sensitivity in pain-free male subjects per se. Notably, previous studies have demonstrated that intramuscular propranolol provides an immediate analgesic response [22] to pain from intramuscular injection of serotonin [21]. However, the intramuscular injection of propranolol in these studies may have resulted in a higher local concentration of propranolol, compared to the systemic (i.e. oral) administration used in the current study.

### 4.3 Central pain modulatory mechanisms

Temporal summation of pain assesses pain facilitation, while CPM and OA assess endogenous pain inhibition in humans [26]. For CPM, a functioning inhibitory system is commonly reported in healthy subjects, corresponding to a significant increase in the perceived intensity of a test stimulus during the delivery of a conditioning stimulus [77], similar to what was found in the current study. OA represents a disproportional reduction in perceived pain following a slight decrease in painful stimulus intensity in healthy subjects [30, 49], which the current study also demonstrated.

Administration of ketamine influences CPM but not OA [32]. Furthermore, differences in brain activity have been recorded during an OA and CPM paradigm [78], suggesting that the mechanisms underlying CPM and OA are different. A recent study found that increased HRV was associated with lower pain ratings during an offset analgesia paradigm [79], suggesting an association between OA and the ANS. Nahman-Averbuch et al. [42] found that ANS activity in woman was associated with an OA-effect whereas ANS activity in men was associated with a CPM-effect, indicating sex-dependent effects, which should be investigated in future studies. It could be assumed that measures of ANS activity are associated with CPM, since afferent baroreceptor signals have been implicated in the modulation of pain perception via medullary and mesencephalic neural circuitry, influencing descending pain inhibition [58, 59] and medullary transections, reducing diffuse noxious inhibitory control (the preclinical counterpart to CPM) in rats [80] – presenting promising avenues for future research in humans. Schweinhardt et al. [81] investigated 39 healthy males and studied the effect of propranolol on heat pain sensitivity and a found small decreased effect size for propranolol compared with placebo, which could explain that the peripheral contribution of propranolol is limited, which could be an explanation for why OA did not change in the current study.

Maekawa et al. [82], compared infusion of propranolol to saline and fond propranolol to lower heart rate at baseline and during CPT, which is similar to the IBI findings from the current study.
4.4 Limitations

The current study found an increase in HRV following propranolol administration but did not find this to be associated with differences in efficacy of any facilitatory or inhibitory pain mechanisms. Due to safety reasons, the current study administrated a low single-dose propranolol to healthy young males who showed normal heart rate and blood pressure. This could limit a potential effect of propranolol on central pain processing mechanisms, rendering differences between propranolol and the placebo undetectable. Contrasting this, similar doses, as used in the current study, are used by students for exam-related anxiety [83] and similar low doses have previously lowered pain ratings in patients with fibromyalgia and TMD [15]. Moreover, 40 mg represents the initial maximal recommend dosage for hypertension and tachycardia. Despite this, the current study did find effects on heart rate, blood pressure and HRV but no effect and central pain mechanism. It is unknown if more substantial parasympathomimetic effects would modulate pain processing mechanisms in healthy subjects.

The most significant ANS responsiveness aberrations related to pain have been observed in chronic pain patients suffering from, e.g. fibromyalgia [15] or TMD [16] and are generally related to a decrease of parasympathetic resting activity. Prolonged suppression of parasympathetic activity is thus not necessarily reproducible in an acute design as applied in the present study. Several previous studies support an antihyperalgesic [23, 84] and a potential analgesic [15, 16] effect of propranolol but the linkage between these effects is unclear. The present study did not employ an experimental model of evoked hyperalgesia such as intradermal capsaicin [85], burn-injury or L-menthol [86] evoked secondary hyperalgesia and thus cannot corroborate previous finding related to propranolol-induced antihyperalgesia.

5 Conclusion

The current study found that propranolol decreased heart rate, blood pressure and increased HRV but had no impact on pain sensitivity or pain modulatory status in healthy male subjects.

Authors’ statements

Research funding: The authors thank The Innovation Fund Denmark (j.no. 136-2014-5), The Shionogi Science Program and the TaNeDS Europe grant for providing the opportunity to conduct the study.

Conflict of interest: Masato Tsukamoto is an employee of Asahi Kasei Pharma Corporation.

Informed consent: All participants were given oral and written information and signed written informed consent prior to the initiation of the study.

Ethical approval: The study complied with the Helsinki Declaration, was approved by the local Ethical Committee (reference number: N-20120043), and registered at ClinicalTrials.gov (registration number: NCT02808611).

References


[76] Petersen KK, Graven-Nielsen T, Simonsen O, Laursen MB, Arendt-Nielsen L. Preoperative pain mechanisms assessed by...


